Title | Rationale and Design of Sympathetic Mapping/Ablation of Renal Nerves Trial (SMART) for the Treatment of Hypertension: a Prospective, Multicenter, Single-Blind, Randomized and Sham Procedure-Controlled Study |
Authors | Wang, Jie Sun, Ningling Ge, Junbo Jiang, Hong Yin, Yuehui Chen, Minglong Wang, Yue Yao, Chen Yan, Xiaoyan Sobotka, Paul A. Huo, Yong |
Affiliation | Columbia Univ, Coll Phys & Surg, Dept Med, Div Cardiol, New York, NY 10032 USA Nanjing Med Univ, Acad Clin & Translat Res Jiangsu Prov, Affiliated Hosp 1, Nanjing 210029, Peoples R China Peking Univ, Heart Ctr, Dept Hypertens, Peoples Hosp, Beijing 100044, Peoples R China Fudan Univ, Zhongshan Hosp, Dept Cardiol, Shanghai 200032, Peoples R China Wuhan Univ, Dept Cardiol, Renmin Hosp, Wuhan 430060, Peoples R China Chongqing Med Univ, Dept Cardiol, Affiliated Hosp 2, Chongqing 400010, Peoples R China Nanjing Med Univ, Dept Cardiol, Affiliated Hosp 1, Nanjing 210029, Peoples R China Peking Univ, Clin Res Inst, Beijing 100191, Peoples R China Peking Univ First Hosp, Dept Biostat, Beijing 100034, Peoples R China Peking Univ First Hosp, Div Cardiol, Beijing 100034, Peoples R China |
Keywords | TREATMENT-RESISTANT HYPERTENSION BLOOD-PRESSURE ELECTRICAL-STIMULATION AUTONOMIC RESPONSES ARTERIAL NERVES UNITED-STATES DENERVATION PREVALENCE CATHETER COMBINATION |
Issue Date | Aug-2022 |
Publisher | JOURNAL OF CARDIOVASCULAR TRANSLATIONAL RESEARCH |
Abstract | Renal denervation (RDN) is proposed as a durable and patient compliance independent treatment for hypertension. However, 20-30% non-responder after RDN treatment weakened the therapeutic effect, which may be due to blind ablation. The renal nerve mapping/selective ablation system developed by SyMap Medical Ltd (Suzhou), China, has the function of mapping renal sympathetic/parasympathetic nerve sites and selectively removing renal sympathetic nerves and is expected to meet the urgent unmet clinical need of targeted RDN. The "Sympathetic Mapping/Ablation of Renal Nerves Trial" (SMART) is a prospective, multicenter, randomized, single-blinded, sham procedure-controlled trial, to evaluate the safety and efficacy of targeted renal sympathetic denervation in patients with essential and uncontrolled hypertension. The study is the first clinical registry trial using a targeted RDN for the treatment of uncontrolled hypertension; the dual-endpoint design can answer the question of how many antihypertensive drugs can be reduced in patients after RDN. The trial is registered on clinicaltrials.gov NCT02761811. |
URI | http://hdl.handle.net/20.500.11897/652584 |
ISSN | 1937-5387 |
DOI | 10.1007/s12265-022-10307-z |
Indexed | SCI(E) |
Appears in Collections: | 人民医院 第一医院 |